Teranga Pharma, a pharmaceutical company based in Senegal, has produced the first [1] treatment for sickle cell disease manufactured in Africa.
This development marks a significant shift in medical autonomy for the region. By producing the drug locally in Dakar, the company aims to lower costs and increase accessibility for patients who previously relied on expensive imported medications.
Sickle cell disease disproportionately affects the African continent, which accounts for nearly 80 percent [2] of global cases. The reliance on foreign pharmaceutical imports has historically created financial barriers for many patients seeking essential care.
Teranga Pharma announced the breakthrough in July 2026 [3]. The company said the goal of the initiative is to provide an affordable, locally produced drug to reduce the dominance of costly imported medicines in the African market.
The production takes place in Dakar, Senegal, where the company is working to establish a sustainable supply chain for the treatment. This move is intended to address the specific healthcare needs of the local population while demonstrating the capacity for high-level pharmaceutical manufacturing within the continent.
While the treatment represents a milestone in regional healthcare, the company is focusing on the logistical challenges of distribution. Ensuring the drug reaches rural areas remains a priority as Teranga Pharma seeks to scale its operations to meet the demand of a widespread genetic condition.
“Teranga Pharma has produced the first treatment for sickle cell disease manufactured in Africa.”
The launch of a locally manufactured sickle cell treatment in Senegal signals a strategic move toward pharmaceutical sovereignty in Africa. By shifting production from global imports to regional manufacturing, the continent can potentially lower the cost of life-saving medicine and reduce vulnerability to international supply chain disruptions for a disease that is endemic to the region.
